SanBio and Sumitomo Dainippon Pharma Announce Topline Results from a Phase 2b Study in the U.S. Evaluating SB623, a Regenerative Cell Medicine for the Treatment of Patients with Chronic Stroke
SanBio Receives $20 Million Grant from CIRM for Stroke Clinical Trial（264KB）
New Study Reveals Economic Impact of Patients with Traumatic Brain Injury（140KB）
Study of SanBio’s Stem Cell Treatment for Stroke Receives Innovation Award from American Heart Association（168KB）
First Patient is Enrolled in Global STEMTRA Trial for Traumatic Brain Injury in Japan（187KB）
First Patient is Randomized in STEMTRA Trial For Traumatic Brain Injury（92KB）
SanBio Presents Interim Results of Chronic Stroke Phase 1/2a Clinical Trial at International Society of Stem Cell Research Annual Meeting（92KB）
SanBio publishes interim 12-month Phase 1/2a clinical trial results in the leading medical journal, Stroke（112KB）
SanBio Granted Key Patent in Treatment for Macular Degeneration（90KB）
University Hospitals Case Medical Center Randomizes the First Patient in ACTIsSIMA Trial for Chronic Stroke（199KB）
